Stryker Corp
$115.42B- Market cap
- $103.57B
- Debt
- +$15.86B
- Cash
- −$4.01B
Capital structure 87% equity / 13% debt · EV / Revenue 4.60x · EV proxy / EBITDA proxy 17.87x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $103.57B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
FY 2025 ·
Decision snapshot: SYK stock price vs ALGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ALGN's multiple
Needs ALGN P/E.
Implied fair value · at SYK's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 87% equity / 13% debt · EV / Revenue 4.60x · EV proxy / EBITDA proxy 17.87x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
STRYKER CORP · implied price per share
Bear
$103.67
Base
$129.90
Bull
$165.28
ALIGN TECHNOLOGY, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
SYK vs ABT
JOHNSON & JOHNSON
SYK vs JNJ
BAXTER INTERNATIONAL INC
SYK vs BAX
INTUITIVE SURGICAL INC
SYK vs ISRG
ARTIVION, INC.
SYK vs AORT
ABERCROMBIE & FITCH CO /DE/
SYK vs ANF
Envista Holdings Corp
SYK vs NVST
HENRY SCHEIN INC
SYK vs HSIC
PATTERSON COMPANIES, INC.
SYK vs PDCO
3M CO
SYK vs MMM
DANAHER CORP /DE/
SYK vs DHR
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe SYK can sustain >10% revenue growth and maintain current margins (e.g., operating margin ~19.5%) to justify its 41.0x P/E, then consider buying or holding; otherwise, trim or avoid because the stock is priced ~20% above the ALGN-based P/E-implied level and is vulnerable to multiple compression.
SYK's market price ($344.60) sits materially above the P/E-implied price ($276.66), implying a ~19.7% downside to the ALGN-based multiple. The stock is above ALGN-implied band but still inside its historical valuation band, indicating investor willingness to pay a premium versus ALGN. Premium multiples (P/E, EV/EBITDA, P/S) drive most of the gap rather than inferior operating performance.
Supporting Metrics